Lupin launches Meloxicam capsules
28 December 2020 | News
Meloxicam capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex® capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc, and indicated for management of osteoarthritis (OA) pain
Source credit: Shutterstock
Lupin Limited a global pharmaceutical company, announced the launch of Meloxicam capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration.
Meloxicam capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex® capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc, and indicated for management of osteoarthritis (OA) pain.
Meloxicam capsules (RLD: Vivlodex®) had an annual sales of approximately $11 million in the US (IQVIA MAT October 2020).
